Jacque Sokolov, MD, president and chairman at SSB Solutions, previews his keynote presentation and discusses the unique, shifting health care atmosphere leading into the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.
Jacque Sokolov, MD, president and chairman at SSB Solutions, previews his keynote presentation and discusses the unique, shifting health care atmosphere leading into the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023, which runs from April 26-28 in Orlando, FL.
Transcript
What are you most looking forward to at this year’s meeting?
This spring forum in 2023 is arguably one of the most unique forums I think I've ever had the opportunity to keynote. The year is post pandemic, and now we're endemic in terms of COVID-19. The clinical, business, and operational models that are transforming health care have been amplified, and we're all starting to understand how they are affecting everyday life in terms of the health care sectors we deal with.
What are the main drivers of health care market transformation that you’ll be discussing in your keynote presentation?
There'll be 3 areas of transformation that will be focused on. From the clinical transformation area, there could be many, but I'm picking biopharma and AI [artificial intelligence] as the 2 areas that I think are most impactful. From a business transformation perspective, I think it is the super aggregators and the consolidation of certain sectors of the health care economy. And from an operating perspective, I think, quite candidly, it is the appreciation of the workforce burnout and disparity issues that we've seen as a result of COVID-19 and the stress on the US health care system.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More